| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | -32146.67% | — | — |
| EBITDA Margin | — | — | — | — | -31703.33% | — | — |
| Net Margin | — | — | — | — | -31800.67% | — | — |
| Current Ratio | 0.37 | 3.52 | 4.11 | 9.53 | 12.48 | 7.46 | — |
| Quick Ratio | 0.37 | 3.52 | 4.11 | 9.53 | 12.48 | 7.46 | — |
| Debt / Equity | — | — | — | — | — | — | — |
| ROE | 164.71% | -489.14% | -174.70% | -59.05% | -45.25% | -17.07% | — |
| ROA | -431.06% | -133.10% | -103.18% | -47.17% | -37.50% | -14.64% | — |
| Asset Turnover | — | — | — | — | 0.00 | — | — |
| Book Value / Share | -0.62 | 0.29 | 1.48 | 4.63 | 6.10 | — | — |
BioAtla, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the development of Conditionally Active Biologics (CAB) antibody therapeutics designed for solid tumors. The CAB platform enables antibodies to activate selectively in the tumor microenvironment, enhancing safety and efficacy by minimizing activity in healthy tissues while targeting cancer-specific conditions. Key programs include ozuriftamab vedotin (Oz-V), a ROR2-targeting antibody-drug conjugate advancing in trials for HPV-positive oropharyngeal squamous cell carcinoma and head and neck cancers; mecbotamab vedotin (Mec-V), an AXL-targeting ADC evaluated in treatment-refractory soft tissue sarcomas and non-small cell lung cancer; and BA3182, a bispecific T-cell engager targeting EpCAM and CD3 for metastatic adenocarcinomas. BioAtla, Inc. focuses on oncology, leveraging proprietary technologies like Comprehensive Integrated Antibody Optimization (CIAO) to create next-generation biologics with improved therapeutic indices for challenging solid tumors.